Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pilot EEG Study of CT1812 in Mild to Moderate Alzheimer's Disease
2019-003552-36Phase 2Completed
- Sponsor
- Cognition Therapeutics, Inc.
- Start
- Oct 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of zervimesine in Alzheimer's disease (AD), sponsored by Cognition Therapeutics, Inc. Primary endpoints: Safety and tolerability of CT1812 over 29 days and Pharmacokinetics of CT1812. Started Oct 2019; status: completed.
02
Drugs
zervimesine
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on 2019-003552-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003552-36.